Combretastatin A4 phosphate

Anti-Cancer Drugs

Volumn 15, Issue 3, 2004, Pages 179-187

  West, Catharine M L ^a   Price, Pat ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Magnetic resonance imaging; Positron emission tomography; Vascular targeting agent

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ACTIN; ANTIBODY; CARBOPLATIN; CARCINOEMBRYONIC ANTIBODY; CISPLATIN; COLCHICINE; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GADOLINIUM PENTETATE; GROWTH FACTOR; IODINE 125; MITOFLAXONE; MYOSIN; MYOSIN LIGHT CHAIN; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; TOXIN; TUBULIN; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ABDOMINAL CRAMP; ACTIN POLYMERIZATION; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ATAXIA; BLOOD TOXICITY; BLOOD VESSEL PERMEABILITY; CARDIOTOXICITY; CELL GROWTH; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM CELL; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; HYPERTHERMIA; INTESTINE ISCHEMIA; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERIZATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PRURITUS; QT PROLONGATION; RADIOIMMUNOTHERAPY; REVIEW; SYNCOPE; THYROID CANCER; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STILBENES; TECHNOLOGY, PHARMACEUTICAL;

EID: 1842607060     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200403000-00001     Document Type: Review

References (83)

1. Harris SR, Thorgeirsson UP. Tumor angiogenesis: biology and therapeutic prospects. In Vivo 1998; 12:563-570.
2. Denekamp J. The current status of targeting tumor vasculature as a means of cancer therapy: an overview. Int J Radiat Biol 1991; 60:401-408.
3. Kakolyris S, Fox SB, Koukourakis M, Giatromanolaki A, Brown N, Leek RD, et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. Br J Cancer 2000; 82:844-851.
4. Harris AL. Hypoxia - a key regulatory factor in tumor growth. Nat Rev Cancer 2002; 2:38-47.
5. Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 1987; 50:119-131.
6. Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR, et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 1988; 34:200-208.
7. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989; 45:209-211.
8. Pettit GR, Temple C, Narayanan VL, Varma R, Simpson MJ, Boyd MR, et al. Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 1995; 10:299-309.
9. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57:1829-1834.
10. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 1982; 45:136-139.
11. Denekamp J. Vascular endothelium as the vulnerable element in tumors. Acta Radiol Oncol 1984; 23:217-225.
12. Thorpe PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: meeting overview. Cancer Res 2003; 63:1144-1147.
13. Bloemendal HJ, Logtenberg T, Voest EE. New strategies in anti-vascular cancer therapy. Eur J Clin Invest 1999; 29:802-809.
14. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst 1989; 81:1005-1013.
15. Hill S, Williams KB, Denekamp J. Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur J Cancer Clin Oncol 1989; 25:1419-1424.
16. Bibby MC, Double JA, Loadman PM, Duke CV. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst 1989; 81:216-220.
17. Kallinowski F, Schaefer C, Tyler G, Vaupel P. In vivo targets of recombinant human tumour necrosis factor-alpha: blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br J Cancer 1989; 60:555-560.
18. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991; 27:482-487.
19. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993; 90:8996-9000.
20. Rustin GJ, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003; 88:1160-1167.
21. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003; 88:1844-1850.
22. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003; 4:141-148.
23. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 1993; 9:1320-1324.
24. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 1996; 27:S86-S88.
25. Woods JA, Hadfield JA, Pettit GR, Fox BW, McGown AT. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 1995; 71:705-711.
26. Horsman MR, Ehrnrooth E, Ladekarl M and Overgaard J. The effect of combretastatin A-4 disodium phosphate in a C3 H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 1998; 42:895-898.
27. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999; 59:1626-1634.
28. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61:6413-6422.
29. Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li LY, Smulson ME. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 1998; 58:4510-4514.
30. Ahmed B, Van Eijk LI, Bouma-Ter Steege JC, Van Der Schaft DW, Van Esch AM, Joosten-Achjanie SR, et al. Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int J Cancer 2003; 105:20-25.
31. Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR, et al. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res 2002; 8:2735-2741.
32. Boehle AS, Sipos B, Kliche U, Kalthoff H, Dohrmann P. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann Thorac Surg 2001; 71:1657-1665.
33. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999; 81:1318-1327.
34. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumor vascular targeting activity in vivo. Anticancer Res 2001; 21:93-102.
35. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002; 99:2060-2069.
36. Griggs J, Hesketh R, Smith GA, Brindle KM, Metcalfe JC, Thomas GA, et al. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br J Cancer 2001; 84:832-835.
37. Griggs J, Skepper JN, Smith GA, Brindle KM, Metcalfe JC, Hesketh R. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am J Pathol 2002; 160:1097-1103.
38. McGown AT, Fox BW. Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines. Cancer Chemother Pharmacol 1990; 26:79-81.
39. Nabha SM, Wall NR, Mohammad RM, Pettit GR, Al-Katib AM. Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines. Anticancer Drugs 2000; 11:385-392.
40. Prise VE, Honess DJ, Stratford MR, Wilson J, Tozer GM. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 2002; 21:717-726.
41. Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, O'Brien PE. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 2001; 7:1052-1060.
42. Griggs J, Brindle KM, Metcalfe JC, Hill SA, Smith GA, Beauregard DA, et al. Potent anti-metastatic activity of combretastatin-A4. Int J Oncol 2001; 19:821-825.
43. Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR, et al. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy. Anticancer Drugs 2001; 12:57-63.
44. Rojiani AM, Li L, Rise L, Siemann DW. Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. Acta Oncol 2002; 41:98-105.
45. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001; 61:6811-6815.
46. Parkins CS, Holder AL, Hill SA, Chaplin DJ, Tozer GM. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 2000; 83:811-816.
47. Landuyt W, Verdoes O, Darius DO, Drijkoningen M, Nuyts S, Theys J, et al. Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 2000; 36:1833-1843.
48. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62: 3408-3416.
49. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003; 21:2815-2822.
50. Stevenson JP, Gallagher M, Sun W, Algazy KM, Vaughn DJ, Haller DG, et al. Phase I/pharmacokinetic trial of the endothelial toxin combretastatin A4P (CA4P) administered as an iv bolus on a daily x 5 schedule every 21 days. Proc Am Ass Cancer Res 2000; 41:544.
51. Bilenker JH, Stevenson JP, Rosen MA, Gallagher M, Flaherty KT, Algazy KM, et al. Phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with carboplatin in patients with advanced cancer. Proc Am Soc Clin Oncol 2003; 22:abstr 889.
52. Collins JM. Functional imaging in phase I studies: decorations or decision making? J Clin Oncol 2003; 21:2807-2809.
53. 1H MRI. Int J Radiat Oncol Biol Phys 1998; 42:891-894.
54. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. Assessment of anti-angiogenic and anti-vascular therapeutics using magnetic resonance imaging: recommendations for appropriate methodology for clinical trials. Proc Am Ass Cancer Res 2003; 44:absr 504.
55. Galbraith SM, Lodge MA, Taylor NJ, Rustin GJ, Bentzen S, Stirling JJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumors: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002; 15:132-142.
56. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998; 77:1761-1767.
57. Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumors by dynamic contrast enhanced MRI. NMR Biomed 2002; 15:89-98.
58. Beauregard DA, Pedley RB, Hill SA, Brindle KM. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 2002; 15:99-105.
59. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003; 21:2831-2842.
60. Rosen MA, Englander S, Stevenson J, O'Dwyer PB, Schnall M. Dynamic gadolinium-enhanced MRI of tumors: effects of CA4P on tumor blood flow. Proc Am Soc Clin Oncol 2001; 20:abstr 384.
61. Anderson H, Price P. Blood flow in tumors using PET: a review. Nucl Med Commun 2002; 23:131-138.
62. Anderson H, Yap JT, Wells P, Miller MP, Propper D, Price P, et al. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer 2003; 89:262-267.
63. 2 PET measurements of blood flow in patients with intra-abdominal cancers. Clin Cancer Res 2003; 9:6350-6356.
64. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003; 21:2823-2830.
65. Hill SA, Chaplin DJ, Lewis G, Tozer GM. Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumor models. Int J Cancer 2002; 102:70-74.
66. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995; 72:41-44.
67. Davis PD, Tozer GM, Naylor MA, Thomson P, Lewis G, Hill SA. Enhancement of vascular targeting by inhibitors of nitric oxide synthase. Int J Radiat Oncol Biol Phys 2002; 54:1532-1536.
68. Nelkin BD, Ball DW. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 2001; 8:157-160.
69. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999; 19:189-195.
70. Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 1998; 42:899-903.
71. Li L, Rojiani AM, Siemann DW. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol 2002; 41:91-97.
72. Horsman MR, Murata R. Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 2002; 54: 1518-1523.
73. Horsman MR, Murata R, Breidahl T, Nielsen FU, Maxwell RJ, Stodkiled-Jorgensen H, et al. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 2000; 476:311-323.
74. Landuyt W, Ahmed B, Nuyts S, Theys J, Op de Beeck M, Rijnders A, et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 2001; 49:443-450.
75. Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001; 60:155-161.
76. Pedley RB, El-Emir E, Flynn AA, Boxer GM, Dearling J, Raleigh JA, et al. Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys 2002; 54:1524-1531.
77. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res 2001; 61:4716-4722.
78. Eikesdal HP, Bjerkvig R, Mella O, Dahl O. Combretastatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors. Radiother Oncol 2001; 60:147-154.
79. Eikesdal HP, Bjerkvig R, Raleigh JA, Mella O, Dahl O. Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiother Oncol 2001; 61:313-320.
80. Eikesdal HP, Schem BC, Mella O, Dahl O. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. Int J Radiat Oncol Biol Phys 2000; 46:645-652.
81. Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 2001; 51: 1018-1024.
82. Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000; 20:229-233.
83. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002; 99:1-6.